Skip to main content
. 2020 Sep 18;11(9):778. doi: 10.1038/s41419-020-02972-2

Fig. 2. CS055 shows a superior resensitization effect than romidepsin in potentiation of ABT-199 lethality in acute myeloid leukemia (AML) cells.

Fig. 2

a Molm-13, b MV4;11, and c OCI-AML3 cells were exposed to the indicated concentrations of ABT-199 ± CS055 (0.25 µM for Molm-13 and MV4;11, and 1.0 µM for OCI-AML3) or romidepsin (1.5 nM for Molm-13 and MV4;11, and 2.5–3 nM for OCI-AML3) for 48 h, after which the percentage of apoptotic cells was determined using Annexin V/PI double staining by flow cytometry. d, e Western blot analysis was performed to validate downregulation efficiency of HDAC1 and HDAC2 in MV4;11 and OCI-AML3 cells. f, g Cells were exposed to ABT-199 (50 nM for MV4;11, 1.0 µM for OCI-AML3), and then the percentage of apoptotic cells was determined by flow cytometry. Scramble shRNA-transfected cells exposed for 48 h to combined treatment with ABT-199 (50 nM for MV4;11, 1.0 µM for OCI-AML3) and CS055 (0.5 µM for MV4;11, 1.0 µM for OCI-AML3) serve as a positive control. Values indicate mean ± SD for at least three independent experiments performed in triplicate (*P < 0.05, **P < 0.01, ***P < 0.001, ns not significant).